Targeting DNA to Cells with Basic Fibroblast Growth Factor (FGF2)
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Ligand-mediated targeting of DNA was validated by condensing a plasmid DNA encoding the beta-galactosidase (beta-gal) gene with a basic fibroblast growth factor (FGF2) that was first chemically conjugated to polylysine (K). The conditions that gave optimal binding of this FGF2 to DNA also generated the highest level of beta-gal expression when added to FGF2 target cells like COS-1, 3T3, baby hamster kidney (BHK), or endothelial cells. This beta-gal activity increased in a time- and dose-dependent manner and was dependent on the inclusion of FGF2 in the complex. FGF receptor specificity was demonstrated by competition of the complex with FGF2 and heparin, and by the failure of cytochrome c or histone H1 to mimic the gene-targeting effects of FGF2. The expression of beta-gal was also endosome dependent because chloroquine increased beta-gal expression 8-fold and endosome disruptive peptides increased expression of beta-gal 26-fold. Taken together these findings establish that DNA can be introduced into cells through the high affinity FGF receptor complex, and while its efficiency will require significant enhancements to achieve sustained and elevated transgene expression, the possibility that the technique could be used to deliver DNAs encoding cytotoxic molecules is discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yayon, A., Klagsbrun, M., Esko, J. D., Leder, P., & Ornitz, D. M. (1991) · Cell · doi:10.1016/0092-8674(91)90512-w · Cited by 2,440
Requirement of Heparan Sulfate for bFGF-Mediated Fibroblast Growth and Myoblast Differentiation
Rapraeger, A. C., Krufka, A., & Olwin, B. B. (1991) · Science · doi:10.1126/science.1646484 · Cited by 1,508
Counterion-induced condensation of deoxyribonucleic acid. A light-scattering study
Wilson, R. W., & Bloomfield, V. A. (1979) · Biochemistry · doi:10.1021/bi00578a009 · Cited by 630
Cited by
Prospects for cationic polymers in gene and oligonucleotide therapy against cancer
Merdan, T., Kopec̆ek, J., & Kissel, T. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00046-7 · Cited by 785
Internalization of HIV-1 Tat Requires Cell Surface Heparan Sulfate Proteoglycans
Tyagi, M., Rusnati, M., Presta, M., & Giacca, M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006701200 · Cited by 719
REGULATION OF GENE EXPRESSION BY DIETARY FAT
Jump, D. B., & Clarke, S. D. (1999) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.19.1.63 · Cited by 663
Design and gene delivery activity of modified polyethylenimines
Kircheis, R., Wightman, L., & Wagner, E. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00202-2 · Cited by 651
Vector unpacking as a potential barrier for receptor-mediated polyplex gene delivery
Schaffer, D. V., Fidelman, N. A., Dan, N., & Lauffenburger, D. A. (2000) · Biotechnology and Bioengineering · doi:10.1002/(sici)1097-0290(20000305)67:5<598::aid-bit10>3.0.co;2-g · Cited by 524
Delivery of bioactive molecules into the cell: the Trojan horse approach
Dietz, G. P. H., & Bähr, M. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.03.005 · Cited by 469
Polymer systems for gene delivery—Past, present, and future
Wong, S. Y., Pelet, J. M., & Putnam, D. (2007) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.05.007 · Cited by 427
Current Progress in Gene Delivery Technology Based on Chemical Methods and Nano-Carriers
Jin, L., Zeng, X., Liu, M., Deng, Y., & He, N. (2014) · Theranostics · doi:10.7150/thno.6914 · Cited by 388
“For example, PEG was introduced to reduce the cytotoxicity [258], target ligands such as transferrin, folate, antibodies and basic fibroblast growth factor were tethered to promote complex cellular uptake [259-262], and histidine derivatives were grafted to improve the endosomal escape of the complexes [263].”
MethodGene delivery with synthetic (non viral) carriers
Brown, M. D., Schätzlein, A. G., & Uchegbu, I. F. (2001) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00861-4 · Cited by 367
Intracellular trafficking of nonviral vectors
Medina-Kauwe, L. K., Xie, J., & Hamm-Alvarez, S. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302592 · Cited by 346
Recent advances in the biochemistry and molecular biology of fatty acyl desaturases
Tocher, D. R., Leaver, M. J., & Hodgson, P. A. (1998) · Progress in Lipid Research · doi:10.1016/s0163-7827(98)00005-8 · Cited by 312
Stabilization of poly-l-lysine/DNA polyplexes for in vivo gene delivery to the liver
Kwoh, D. Y., Coffin, C. C., Lollo, C. P., Jovenal, J., Banaszczyk, M. G., Mullen, P., Phillips, A., Amini, A., Fabrycki, J., Bartholomew, R. M., et al. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00274-7 · Cited by 276
Synthesis of Poly(β-amino ester)s with Thiol-Reactive Side Chains for DNA Delivery
Zugates, G. T., Anderson, D. G., Little, S. R., Lawhorn, I. E. B., & Langer, R. (2006) · Journal of the American Chemical Society · doi:10.1021/ja061570n · Cited by 204
The role of sphingolipids in the process of signal transduction
Riboni, L., Viani, P., Bassi, R., Prinetti, A., & Tettamanti, G. (1997) · Progress in Lipid Research · doi:10.1016/s0163-7827(97)00008-8 · Cited by 190
Non-viral vectors in cancer gene therapy: principles and progress
Schatzlein, A. G. (2001) · Anti-Cancer Drugs · doi:10.1097/00001813-200104000-00001 · Cited by 188
Rosenfeld, E., & Beauvoit, B. (2003) · Yeast · doi:10.1002/yea.1026 · Cited by 149
Nanodelivery in airway diseases: Challenges and therapeutic applications
Roy, I., & Vij, N. (2010) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2009.07.001 · Cited by 137
Receptor-mediated gene transfer vectors: progress towards genetic pharmaceuticals
Molas, M., Gomez-Valades, A., Vidal-Alabro, A., Miguel-Turu, M., Bermudez, J., Bartrons, R., & Perales, J. (2003) · Current Gene Therapy · doi:10.2174/1566523034578195 · Cited by 33
Metadata
- Authors
- Sosnowski, B. A., Gonzalez, A. M., Chandler, L. A., Buechler, Y. J., Pierce, G. F., & Baird, A.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1996-12
- Volume
- 271
- Issue
- 52
- Pages
- 33647-33653
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1994231905
- Cited by
- 151
- References
- 3
- FWCI
- 3.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.